Subtopic Deep Dive

Irreversible Electroporation Tissue Ablation
Research Guide

What is Irreversible Electroporation Tissue Ablation?

Irreversible electroporation (IRE) tissue ablation uses micro- to millisecond electrical pulses to induce irreversible cell membrane permeabilization, causing non-thermal cell necrosis while preserving extracellular matrix and vital structures.

IRE emerged as a focal therapy for tumors in 2007 with foundational studies demonstrating efficacy in mouse models and blood vessel safety (Rubinsky et al., 2007; Al-Sakere et al., 2007). Over 10 key papers since 2007, cited up to 757 times, cover preclinical to clinical applications in liver, prostate, and pancreatic cancers. Clinical safety for hepatic tumors near vital structures was confirmed in human trials (Cannon et al., 2012).

Curated Papers

Key Challenges

Why It Matters

IRE enables minimally invasive ablation of inoperable tumors adjacent to blood vessels and bile ducts, reducing complications from thermal damage seen in radiofrequency ablation (Maor et al., 2007; Cannon et al., 2012). It expands treatment options for liver and pancreatic cancers, with early efficacy shown in proximity to vital structures (Cannon et al., 2012). Reviews highlight IRE's role in high-voltage pulse therapies alongside electrochemotherapy for solid tumors (Geboers et al., 2020; Jiang et al., 2014).

Key Research Challenges

Optimizing Pulse Parameters

Balancing pulse voltage, duration, and number to achieve complete ablation without muscle contraction remains critical. High-frequency IRE (H-FIRE) addresses contractions but requires parameter refinement (Arena et al., 2011). Jiang et al. (2014) review preclinical thresholds for IRE efficacy.

Preserving Vascular Structures

Ensuring long-term blood vessel integrity during IRE near tumors is essential for clinical safety. Maor et al. (2007) showed no occlusion in pilot studies, but variability in vessel response persists. Clinical translation demands further validation (Cannon et al., 2012).

Clinical Efficacy Metrics

Quantifying long-term tumor control and survival post-IRE is complicated by follow-up biases in failure time studies. Schemper and Smith (1996) provide methods for adjusted follow-up quantification applicable to IRE trials. Cannon et al. (2012) report early efficacy but stress need for survival data.

Essential Papers

A note on quantifying follow-up in studies of failure time

M. Schemper, Terry L. Smith · 1996 · Controlled Clinical Trials · 2.5K citations

Irreversible Electroporation: A New Ablation Modality — Clinical Implications

Boris Rubinsky, Gary Onik, Paul Mikus · 2007 · Technology in Cancer Research & Treatment · 757 citations

Irreversible electroporation (IRE) is a new tissue ablation technique in which micro to millisecond electrical pulses are delivered to undesirable tissue to produce cell necrosis through irreversib...

Tumor Ablation with Irreversible Electroporation

Bassim Al-Sakere, Franck M. André, Claire Bernat et al. · 2007 · PLoS ONE · 465 citations

We report the first successful use of irreversible electroporation for the minimally invasive treatment of aggressive cutaneous tumors implanted in mice. Irreversible electroporation is a newly dev...

Heating technology for malignant tumors: a review

H. Petra Kok, Erik N. K. Cressman, Wim Ceelen et al. · 2020 · International Journal of Hyperthermia · 373 citations

The therapeutic application of heat is very effective in cancer treatment. Both hyperthermia, i.e., heating to 39-45 °C to induce sensitization to radiotherapy and chemotherapy, and thermal ablatio...

The Effect of Irreversible Electroporation on Blood Vessels

Elad Maor, Antoni Ivorra, Jonathan Leor et al. · 2007 · Technology in Cancer Research & Treatment · 356 citations

We present a pilot study on the long term effects of irreversible electroporation (IRE) on a large blood vessel. The study was motivated by the anticipated use of IRE for treatment of cancer tumors...

Electrochemotherapy: from the drawing board into medical practice

Damijan Miklavčič, Barbara Černič Mali, Bor Kos et al. · 2014 · BioMedical Engineering OnLine · 350 citations

High-frequency irreversible electroporation (H-FIRE) for non-thermal ablation without muscle contraction

Christopher B. Arena, Michael B. Sano, John H. Rossmeisl et al. · 2011 · BioMedical Engineering OnLine · 341 citations

Reading Guide

Foundational Papers

Start with Rubinsky et al. (2007) for IRE definition and clinical vision (757 citations), then Al-Sakere et al. (2007) for first in vivo tumor ablation (465 citations), and Maor et al. (2007) for vessel safety (356 citations).

Recent Advances

Study Cannon et al. (2012) for hepatic clinical safety (327 citations), Geboers et al. (2020) for high-voltage applications (338 citations), and Kok et al. (2020) for ablation comparisons (373 citations).

Core Methods

Core techniques: unipolar 100 µs pulses at 1500 V/cm (Rubinsky et al., 2007); H-FIRE bipolar bursts (Arena et al., 2011); numerical modeling of transmembrane voltage (Jiang et al., 2014).

How PapersFlow Helps You Research Irreversible Electroporation Tissue Ablation

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map IRE literature from Rubinsky et al. (2007, 757 citations) to clinical trials like Cannon et al. (2012), revealing connections to H-FIRE (Arena et al., 2011). exaSearch uncovers variants like high-frequency protocols, while findSimilarPapers expands from Al-Sakere et al. (2007) mouse models.

Analyze & Verify

Analysis Agent employs readPaperContent on Rubinsky et al. (2007) to extract pulse protocols, verifies non-thermal claims via verifyResponse (CoVe) against thermal ablation reviews (Kok et al., 2020), and runs PythonAnalysis for statistical modeling of permeabilization thresholds from Jiang et al. (2014). GRADE grading assesses evidence strength in Cannon et al. (2012) safety data.

Synthesize & Write

Synthesis Agent detects gaps in vascular preservation studies post-Maor et al. (2007), flags contradictions between preclinical and clinical efficacy, and uses exportMermaid for IRE protocol flowcharts. Writing Agent applies latexEditText and latexSyncCitations to draft IRE review sections citing Geboers et al. (2020), with latexCompile for publication-ready output.

Use Cases

"Model IRE threshold for liver tumor ablation using data from recent papers"

Research Agent → searchPapers('IRE liver ablation thresholds') → Analysis Agent → runPythonAnalysis (NumPy/pandas fit voltage-duration curves from Jiang et al. 2014) → matplotlib plot of electroporation model.

"Write LaTeX review on IRE vs thermal ablation for pancreatic cancer"

Synthesis Agent → gap detection (IRE clinical gaps) → Writing Agent → latexEditText (draft section), latexSyncCitations (add Cannon et al. 2012), latexCompile → PDF with embedded IRE mechanism diagram.

"Find open-source code for simulating nanoelectroporation in IRE"

Research Agent → paperExtractUrls (from Arena et al. 2011 H-FIRE) → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified simulation notebook for membrane permeabilization.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ IRE papers, chaining citationGraph from Rubinsky et al. (2007) to generate structured report on clinical translation. DeepScan applies 7-step analysis with CoVe checkpoints to verify non-thermal claims in Al-Sakere et al. (2007). Theorizer generates hypotheses on H-FIRE optimization from Arena et al. (2011) and Geboers et al. (2020).

Try Doxa for Irreversible Electroporation Tissue Ablation Research

Frequently Asked Questions

What defines irreversible electroporation tissue ablation?

IRE delivers micro- to millisecond pulses (typically 1000-3000 V/cm) to induce irreversible membrane permeabilization and non-thermal necrosis, sparing extracellular matrix (Rubinsky et al., 2007).

What are core IRE methods?

Standard IRE uses 90 eight-pulse trains at 1-5 Hz; H-FIRE employs high-frequency bursts to avoid contractions (Arena et al., 2011). Pulse parameters are tuned per tissue type (Jiang et al., 2014).

What are key papers on IRE?

Rubinsky et al. (2007, 757 citations) introduced clinical implications; Al-Sakere et al. (2007, 465 citations) showed tumor ablation in mice; Cannon et al. (2012, 327 citations) reported hepatic safety.

What open problems exist in IRE research?

Challenges include standardizing protocols across tissues, long-term recurrence rates, and integration with immunotherapy. Vascular effects need extended trials beyond Maor et al. (2007); survival metrics require bias correction (Schemper and Smith, 1996).